Hi,
moomoo ID:NaN
Log Out
English
Back
Log in to access Online Inquiry

Forward Pharma A/S (NASDAQ:FWP) & Avalo Therapeutics (NASDAQ:AVTX) Head to Head Survey

Defense World ·  {{timeTz}}

Forward Pharma A/S (NASDAQ:FWP – Get Rating) and Avalo Therapeutics (NASDAQ:AVTX – Get Rating) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their analyst recommendations, institutional ownership, profitability, earnings, dividends, risk and valuation.

Profitability

This table compares Forward Pharma A/S and Avalo Therapeutics' net margins, return on equity and return on assets .

Get Forward Pharma A/S alerts:
Net Margins Return on Equity Return on Assets
Forward Pharma A/S N/A N/A N/A
Avalo Therapeutics -1,896.95% -449.27% -106.25%

Analyst Recommendations

This is a breakdown of recent ratings for Forward Pharma A/S and Avalo Therapeutics, as provided by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Forward Pharma A/S 0 0 0 0 N/A
Avalo Therapeutics 0 1 2 0 2.67
Avalo Therapeutics has a consensus price target of $30.00, suggesting a potential upside of 615.99%. Given Avalo Therapeutics' higher probable upside, analysts plainly believe Avalo Therapeutics is more favorable than Forward Pharma A/S.

Institutional and Insider Ownership

13.0% of Forward Pharma A/S shares are held by institutional investors. 71.5% of Forward Pharma A/S shares are held by company insiders. Comparatively, 45.4% of Avalo Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Volatility & Risk

Forward Pharma A/S has a beta of 1.36, indicating that its stock price is 36% more volatile than the S&P 500. Comparatively, Avalo Therapeutics has a beta of 1.3, indicating that its stock price is 30% more volatile than the S&P 500.

Earnings & Valuation

This table compares Forward Pharma A/S and Avalo Therapeutics' top-line revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Forward Pharma A/S N/A N/A -$1.89 million N/A N/A
Avalo Therapeutics $5.40 million 7.30 -$84.38 million N/A N/A

Forward Pharma A/S has higher earnings, but lower revenue than Avalo Therapeutics.

Summary

Forward Pharma A/S beats Avalo Therapeutics on 7 of the 10 factors compared between the two stocks .

About Forward Pharma A/S

(Get Rating)

Forward Pharma A/S does not have significant operations. Previously, it operated as a biopharmaceutical company that focused on developing FP187 proprietary formulation of dimethyl fumarate for the treatment of inflammatory and neurological indications. Forward Pharma A/S was incorporated in 2005 and is headquartered in Copenhagen, Denmark.

About Avalo Therapeutics

(Get Rating)

Avalo Therapeutics, Inc., a clinical-stage precision medicine company, discovers, develops, and commercializes targeted therapeutics for patients with unmet clinical need in immunology, immuno-oncology, and rare genetic diseases. It develops AVTX-002, a fully human anti-LIGHT monoclonal antibody, which is under Phase II clinical trial for the treatment of non-eosinophilic asthma, as well as inflammatory bowel disease, including moderate to severe Crohn's disease, and ulcerative colitis; and Phase III clinical trial for the treatment of COVID-19 acute respiratory distress syndrome. The company also engages in developing AVTX-007, a fully human Anti-IL-18 monoclonal antibody that is under Phase I clinical trial for the treatment of still's disease, including adult-onset still's disease and systemic juvenile idiopathic arthritis. Its products for rare genetic diseases in Phase III clinical trials include AVTX-801, a D-galactose substrate replacement therapy for the treatment of phosphoglucomutase 1 deficiency (PGM1), also known as PGM1-CDG; and AVTX-803, a L-fucose substrate replacement therapy for the treatment of LADII, also known as SLC35C1-CDG. The company was formerly known as Cerecor Inc. and changed its name to Avalo Therapeutics, Inc. in August 2021. Avalo Therapeutics, Inc. was incorporated in 2011 and is headquartered in Rockville, Maryland.

Receive News & Ratings for Forward Pharma A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Forward Pharma A/S and related companies with MarketBeat.com's FREE daily email newsletter.

This presentation is for informational and educational use only and is not a recommendation or endorsement of any particular investment or investment strategy. Investment information provided in this content is general in nature, strictly for illustrative purposes, and may not be appropriate for all investors. It is provided without respect to individual investors’ financial sophistication, financial situation, investment objectives, investing time horizon, or risk tolerance. You should consider the appropriateness of this information having regard to your relevant personal circumstances before making any investment decisions. Past investment performance does not indicate or guarantee future success. Returns will vary, and all investments carry risks, including loss of principal. Moomoo makes no representation or warranty as to its adequacy, completeness, accuracy or timeliness for any particular purpose of the above content.

Moomoo is a financial information and trading app offered by Moomoo Technologies Inc.
In the U.S., investment products and services available through the moomoo app are offered by Moomoo Financial Inc., a broker-dealer registered with the U.S. Securities and Exchange Commission (SEC) and a member of Financial Industry Regulatory Authority (FINRA)/Securities Investor Protection Corporation (SIPC).
In Singapore, investment products and services available through the moomoo app are offered through Moomoo Financial Singapore Pte. Ltd. regulated by the Monetary Authority of Singapore (MAS). Moomoo Financial Singapore Pte. Ltd. is a Capital Markets Services Licence (License No. CMS101000) holder with the Exempt Financial Adviser Status. This advertisement has not been reviewed by the Monetary Authority of Singapore.
In Australia, financial products and services available through the moomoo app are provided by Futu Securities (Australia) Ltd, an Australian Financial Services Licensee (AFSL No. 224663) regulated by the Australian Securities and Investment Commission (ASIC). Please read and understand our Financial Services Guide, Terms and Conditions, Privacy Policy and other disclosure documents which are available on our websites https://www.futuau.com and https://www.moomoo.com/au. Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd. and Futu Securities (Australia) Ltd are affiliated companies.